Literature DB >> 7853419

Radon and cancers other than lung cancer in underground miners: a collaborative analysis of 11 studies.

S C Darby1, E Whitley, G R Howe, S J Hutchings, R A Kusiak, J H Lubin, H I Morrison, M Tirmarche, L Tomásek, E P Radford.   

Abstract

BACKGROUND: Exposure to the radioactive gas radon and its progeny (222Rn and its radioactive decay products) has recently been linked to a variety of cancers other than lung cancer in geographic correlation studies of domestic radon exposure and in individual cohorts of occupationally exposed miners.
PURPOSE: This study was designed to characterize further the risks for cancers other than lung cancer (i.e., non-lung cancers) from atmospheric radon.
METHODS: Mortality from non-lung cancer was examined in a collaborative analysis of data from 11 cohorts of underground miners in which radon-related excesses of lung cancer had been established. The study included 64,209 men who were employed in the mines for 6.4 years on average, received average cumulative exposures of 155 working-level months (WLM), and were followed for 16.9 years on average.
RESULTS: For all non-lung cancers combined, mortality was close to that expected from mortality rates in the areas surrounding the mines (ratio of observed to expected deaths [O/E] = 1.01; 95% confidence interval [CI] = 0.95-1.07, based on 1179 deaths), and mortality did not increase with increasing cumulative exposure. Among 28 individual cancer categories, statistically significant increases in mortality for cancers of the stomach (O/E = 1.33; 95% CI = 1.16-1.52) and liver (O/E = 1.73; 95% CI = 1.29-2.28) and statistically significant decreases for cancers of the tongue and mouth (O/E = 0.52; 95% CI = 0.26-0.93), pharynx (O/E = 0.35; 95% CI = 0.16-0.66), and colon (O/E = 0.77; 95% CI = 0.63-0.95) were observed. For leukemia, mortality was increased in the period less than 10 years since starting work (O/E = 1.93; 95% CI = 1.19-2.95) but not subsequently. For none of these diseases was mortality significantly related to cumulative exposure. Among the remaining individual categories of non-lung cancer, mortality was related to cumulative exposure only for cancer of the pancreas (excess relative risk per WLM = 0.07%; 95% CI = 0.01-0.12) and, in the period less than 10 years since the start of employment, for other and unspecified cancers (excess relative risk per WLM = 0.22%; 95% CI = 0.08-0.37).
CONCLUSIONS: The increases in mortality from stomach and liver cancers and leukemia are unlikely to have been caused by radon, since they are unrelated to cumulative exposure. The association between cumulative exposure and pancreatic cancer seems likely to be a chance finding, while the association between cumulative exposure and other and unspecified cancers was caused by deaths certified as due to carcinomatosis (widespread disseminated cancer throughout the body) that were likely to have been due to lung cancers. This study, therefore, provides considerable evidence that high concentrations of radon in air do not cause a material risk of mortality from cancers other than lung cancer. IMPLICATIONS: Protection standards for radon should continue to be based on consideration of the lung cancer risk alone.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7853419     DOI: 10.1093/jnci/87.5.378

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  40 in total

Review 1.  Gallbladder cancer.

Authors:  Mislav Rakić; Leonardo Patrlj; Mario Kopljar; Robert Kliček; Marijan Kolovrat; Bozo Loncar; Zeljko Busic
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

2.  Occupational exposures and risk of pancreatic cancer.

Authors:  Miguel Santibañez; Jesús Vioque; Juan Alguacil; Manuela García de la Hera; Eduardo Moreno-Osset; Alfredo Carrato; Miquel Porta; Timo Kauppinen
Journal:  Eur J Epidemiol       Date:  2010-07-17       Impact factor: 8.082

3.  Lung and stomach cancer associations with groundwater radon in North Carolina, USA.

Authors:  Kyle P Messier; Marc L Serre
Journal:  Int J Epidemiol       Date:  2017-04-01       Impact factor: 7.196

4.  Do occupational exposures in nuclear refineries contribute to mortality from brain cancer?

Authors:  R Kusiak; P Ashmore; D Baris
Journal:  Occup Environ Med       Date:  1997-02       Impact factor: 4.402

Review 5.  Radon gas-the hidden killer: What is the role of family doctors?

Authors:  Juan Antonio Garcia-Rodriguez
Journal:  Can Fam Physician       Date:  2018-07       Impact factor: 3.275

6.  Residential radon and cancers other than lung cancer: a cohort study in Galicia, a Spanish radon-prone area.

Authors:  Raquel Barbosa-Lorenzo; Juan M Barros-Dios; Mónica Raíces Aldrey; Sara Cerdeira Caramés; Alberto Ruano-Ravina
Journal:  Eur J Epidemiol       Date:  2016-03-14       Impact factor: 8.082

7.  County-level radon exposure and all-cause mortality risk among Medicare beneficiaries.

Authors:  Maayan Yitshak-Sade; Annelise J Blomberg; Antonella Zanobetti; Joel D Schwartz; Brent A Coull; Itai Kloog; Francesca Dominici; Petros Koutrakis
Journal:  Environ Int       Date:  2019-06-11       Impact factor: 9.621

8.  Leukemia, lymphoma and multiple myeloma mortality (1950-1999) and incidence (1969-1999) in the Eldorado uranium workers cohort.

Authors:  Lydia B Zablotska; Rachel S D Lane; Stanley E Frost; Patsy A Thompson
Journal:  Environ Res       Date:  2014-02-28       Impact factor: 6.498

9.  An update of cancer mortality among the French cohort of uranium miners: extended follow-up and new source of data for causes of death.

Authors:  Dominique Laurier; Margot Tirmarche; Nicolas Mitton; Madeleine Valenty; Patrick Richard; Serge Poveda; Jean-Marie Gelas; Benoit Quesne
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

10.  Radon and risk of extrapulmonary cancers: results of the German uranium miners' cohort study, 1960-2003.

Authors:  M Kreuzer; L Walsh; M Schnelzer; A Tschense; B Grosche
Journal:  Br J Cancer       Date:  2008-11-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.